发明名称 |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2 |
摘要 |
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2. |
申请公布号 |
US9464287(B2) |
申请公布日期 |
2016.10.11 |
申请号 |
US201013256720 |
申请日期 |
2010.03.16 |
申请人 |
CuRNA, Inc. |
发明人 |
Collard Joseph;Khorkova Sherman Olga;Coito Carlos |
分类号 |
C12N15/113;C07H21/04;A61K48/00;A61K31/7088;A61K31/713 |
主分类号 |
C12N15/113 |
代理机构 |
CuRNA, Inc. |
代理人 |
CuRNA, Inc. ;Browder Monte R. |
主权项 |
1. A method of upregulating a function of and/or the expression of a Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide having SEQ ID NO: 1 in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one single stranded antisense oligonucleotide of about 16 to 34 nucleotides in length that targets and specifically hybridizes to a region of a natural antisense polynucleotide of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide, said natural antisense polynucleotide consisting essentially of SEQ ID NO: 9 thereby upregulating a function of and/or the expression of the Nuclear factor (erythroid-derived 2)-like 2 (NRF2) polynucleotide in patient cells or tissues in vivo or in vitro. |
地址 |
Miami FL US |